ArticleBioengineering & translational medicine2023
Magnetic nanoparticles enhance the cellular immune response of dendritic cell tumor vaccines by realizing the cytoplasmic delivery of tumor antigens.
Article in Bioengineering & translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.MedScience · 2026Review
- Magnetic Fields in Cancer Therapy: Mechanistic Insights, Signaling Pathways, and Evidence from Clinical and In Vitro Studies.Pharmaceutics · 2026Review
- A lymph node-targeted cell-nanoadjuvant conjugate enhances dendritic cell-T cell crosstalk for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Bio-magnetic nanomedicine for targeted drug delivery of breast cancer: green synthesis, functional design, and translational challenges.Breast cancer research : BCR · 2026Review
- Magnetic nanoparticles as promising materials for the future of medicine.Journal of materials science. Materials in medicine · 2026Review
- Cell-type specific activation of the cGAS-STING pathway in tumor immunotherapy: mechanisms and therapeutic implications.Journal of translational medicine · 2026Review
- Stimuli-responsive nanoplatforms for precision activation of the STING pathway in cancer immunotherapy.Frontiers in immunology · 2026Review
- Magnetic hyperthermia as an intracellular immunomodulatory technology: From heat transduction to tumor immune reprogramming.Theranostics · 2026Review
- Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy.Journal of biomedical science · 2025Review
- Dectin-1-targeted pH-responsive liposomal nanoplatform delivering Plantago Asiatica L. acidic polysaccharide for immunomodulation and immunosuppressive breast cancer microenvironment reprogramming.Journal of nanobiotechnology · 2025Article
- Iron Oxide Magnetic Nanoparticles Synthesized by Laser Target Evaporation Method for the Needs of Cancer Immunotherapy.Materials (Basel, Switzerland) · 2025Article
- A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines.Materials today. Bio · 2025Article
- Nanomaterials Application for STING Pathway-Based Tumor Immunotherapy.International journal of nanomedicine · 2025Review
- Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2024Review
- Targeted protein delivery based on stimuli-triggered nanomedicine.Exploration (Beijing, China) · 2024Article
- Dendritic cell therapy for neurospoagioma: Immunomodulation mediated by tumor vaccine.Cell death discovery · 2024Review
- Alleviating Effect of a Magnetite (FeGels (Basel, Switzerland) · 2023Article
- Magnetic nanoparticles enhance the cellular immune response of dendritic cell tumor vaccines by realizing the cytoplasmic delivery of tumor antigens.Bioengineering & translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs)-based tumor vaccines have the advantages of high safety and rapid activation of T cells, and have been approved for clinical tumor treatment. However, the conventional DC vaccines have some severe problems, such as poor activation of DCs in vitro, low level of antigen presentation, reduced cell viability, and difficulty in targeting lymph nodes in vivo, resulting in poor clinical therapeutic effects. In this research, magnetic nanoparticles Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.